Immunogen | IMGN - Przychody Ze Sprzedaży



Obroty Zmiana Data
AbbVie USD 16.62B 840M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Amgen USD 9.9B 340M 2025-12
Astellas Pharma JPY 571.21B 46.89B 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Emergent BioSolutions USD 276.6M 6.1M 2023-12
Exelixis USD 598.66M 860K 2025-12
Halozyme Therapeutics USD 451.76M 97.76M 2025-12
Heron Therapeutics USD 32.81M 3.21M 2024-09
Intrexon USD 717K 511K 2024-06
Karyopharm Therapeutics USD 30.54M 8.24M 2024-12
MacroGenics USD 72.84M 50.6M 2025-09
Nektar Therapeutics USD 24.12M 635K 2024-09
Novartis USD 14.36B 478M 2025-09
Pfizer USD 17.58B 880M 2025-12
Regeneron Pharmaceuticals USD 3.88B 130M 2025-12
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 12.2B 3.19B 2025-12